All In Biotech

Drug Trial Radar · NCT04623671

Intravenous Infusion of CAP-1002 in Patients With COVID-19

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 in Patients With COVID-19 (INSPIRE)

Last checked: Nov 19, 2026Latest source record: Feb 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

55

Actual

Start

Nov 15, 2020

Primary completion

Feb 4, 2022

Study completion Feb 4, 2022

Sponsor

Lead sponsor
Capricor Inc.Industry
Sponsor type
Industry
First posted
Nov 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, Pilot, Phase 2 Exploratory study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition as indicated by life-support measures.

Conditions

  • Covid19

Interventions

  • CAP-1002Biological

    Peripheral infusion of 150 million cardiosphere-derived cells (CDCs)

  • PlaceboBiological

    Matching placebo solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of CAP-1002: Incidence of All-Cause MortalityTime frame: Up to End of Study (Day 90)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California Davis

    Sacramento, California

  • Henry Ford Health System

    Detroit, Michigan

  • PharmaTex Research, LLC

    Amarillo, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.